In addition, Shuttle Pharmaceuticals secured a patent for selective histone deacetylase (HDAC) inhibitors, contributing to its mission to enhance cancer treatments. Moreover, the company faces a ...

Patients in this study have IDH wild-type, methylation negative glioblastoma ... secured a patent for selective histone deacetylase (HDAC) inhibitors, a noteworthy advancement in its mission ...